Teva launches Olanzapine and Fluoxetine Capsules for treatment of depression

Download PDF Copy

Jun 22 2012

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today the launch of Olanzapine and Fluoxetine Capsules USP 6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg, and 12 mg/50 mg, the Company's generic equivalent of Symbyax®.

Symbyax® is marketed by Lilly USA and approved for the acute treatment of treatment-resistant depression and bipolar I depression in adults. The brand product had annual sales of approximately $82 million in the United States, based on IMS sales data.

Source: Teva Pharmaceutical Industries Ltd.

Posted in: Medical Condition News | Pharmaceutical News

Comments (0)

Download PDF Copy

Suggested Reading

Norwegian study shows teens who move more cut their depression risk

Norwegian study shows teens who move more cut their depression risk

High certainty and large rewards boost motivation in formerly depressed individuals

High certainty and large rewards boost motivation in formerly depressed individuals

Cancer-related fatigue and depression found to limit recreational activities in survivors

Cancer-related fatigue and depression found to limit recreational activities in survivors

New research maps neural overlap in insomnia, depression, and anxiety

New research maps neural overlap in insomnia, depression, and anxiety

Multiple health conditions linked to higher depression risk

Multiple health conditions linked to higher depression risk

Ten-year data confirm exercise is a powerful tool against depression

Ten-year data confirm exercise is a powerful tool against depression

Ultra-processed foods increase risk of anxiety and depression, study shows

Ultra-processed foods increase risk of anxiety and depression, study shows

Social media hurts teens with anxiety and depression more than healthy peers

Social media hurts teens with anxiety and depression more than healthy peers

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Study uncovers why anxiety and depression lead to low self-belief